-
Highlighted Tests
-
why choose ambry
More than 1 in 60 people have an inherited cardiovascular condition (CDC Aug 2022). Ambry’s mission is to provide the most advanced genetic testing information available to help you identity those at risk and determine the best treatment options. If we know a patient has a disease-causing genetic change, not only does it mean better disease management, but it also indicates that we can test others in the family and provide them with potentially life-saving information.
Choose from one of our more frequently ordered tests listed below.
TAADNext®
Thoracic aortic aneurysms and dissections (TAAD), Marfan syndrome, and other related disorders are serious genetic conditions that often contribute to sudden cardiac death, so an accurate diagnosis is essential to prevent life-threatening events. TAADNext precisely analyzes 35 genes associated with these disorders, helping you confirm a diagnosis that aids in patient management and treatment options.
FHNext®
Familial hypercholesterolemia (FH) is an inherited disorder characterized by high cholesterol and an increased risk for heart disease. FHNext is a 4-gene panel that analyzes genes associated with familial hypercholesterolemia, which can clarify a diagnosis and allow for individualized disease management and treatment.
LongQTNext™
Long QT syndrome, Brugada syndrome, and short QT syndrome are inherited arrhythmias that are often asymptomatic and can lead to sudden cardiac death. LongQTNext is a 17 gene panel that analyzes genes most commonly associated with these inherited arrhythmias. This test can be an effective way to confirm an arrhythmia disorder and direct medical management and treatment decisions.
RhythmNext™
Inherited arrhythmias such as Brugada syndrome, CPVT, LQTS, and SQTS can often lead to sudden cardiac death. RhythmNext, a 42-gene panel analyzes genes associated with these arrhythmias and can be an effective way of confirming a diagnosis. At-risk individuals are identified with vital information aiding in management and intervention options for both the patient and their family.
HCMNext®
HCMNext is a multi-gene panel that can be ordered individually or on a reflex basis for patients with hypertrophic cardiomyopathy (HCM). Often, HCM can be asymptomatic and sudden death is the first and only symptom. Therefore, genetic testing may be the most effective way of identifying at-risk individuals or confirming a diagnosis. HCMNext includes 30 genes that cause HCM. These genes make up over 80% of known genetic causes of HCM.
-
-
Arrhythmia
-
Targeted Panels
-
Arrhythmia
Targeted Panels
Name TAT Genes LongQTNext™ 14-21 days 17 RhythmNext™ 14-21 days 42 CPVTNext® 14-21 days 4 ARVCNext™ 14-21 days 11
-
-
Comprehensive Testing
-
Arrhythmia
Comprehensive Testing
Name TAT Genes CardioNext® 14-21 days 92 CustomNext-Cardio® 14-21 days 167
-
-
Targeted Panels
-
Cardiomyopathy
-
Targeted Panels
-
Cardiomyopathy
Targeted Panels
Name TAT Genes HCMNext® 14-21 days 30 CMNext® 14-21 days 56 DCMNext® 14-21 days 37 ARVCNext™ 14-21 days 11
-
-
Comprehensive Testing
-
Cardiomyopathy
Comprehensive Testing
Name TAT Genes CardioNext® 14-21 days 92 CustomNext-Cardio® 14-21 days 167
-
-
Targeted Panels
-
Aortic Aneurysms / Dissections
-
Aortic Aneurysms / Dissections
Targeted Panels
Name TAT Genes TAADNext® 14-21 days 35
-
-
Familial Hypercholesterolemia
-
Familial Hypercholesterolemia
Targeted Panels
Name TAT Genes FHNext® 14-21 days 4
-
-
Other Lipid Disorders
-
Targeted Panels
-
Other Lipid Disorders
Targeted Panels
Name TAT Genes FCSNext™ 14-21 days 5 Sitosterolemia 14-21 days 2
-
-
Comprehensive Testing
-
Other Lipid Disorders
Comprehensive Testing
Name TAT Genes CustomNext-Cardio® 14-21 days 167
-
-
Targeted Panels
-
Noonan Syndrome / RASopathies
-
Noonan Syndrome / RASopathies
Targeted Panels
Name TAT Genes NoonanNext™ 14-21 days 18
-